Baidu
map

Intens Care Med:ICU急性肾损伤的预防与肾功能的保护!

2017-06-04 xing.T MedSci原创

由此可见,最近的随机对照试验的结果允许制定新的建议和/或增加以前的建议的强度。另一方面,在许多领域,现有可用的证据仍然不足,主要是由于质量受限的临床试验和报告的不良肾脏结局。

ICU的急性肾损伤(AKI)与死亡率和发病率显著相关。近日,危重病医学领域权威杂志Intensive Care Medicine上发表了一篇研究文章,研究人员旨在明确并更新AKI预防之前的建议,具体包括体液、利尿剂、正性肌力药、升压药、血管扩张剂、激素、营养干预、镇静药、他汀类药物、远程缺血预处理和护理包的作用。

研究人员对发表于1966年至2017年期间对具有AKI风险的成年患者使用上述保护性策略的文献进行了系统地检索。考虑到以下临床状况:大手术、危重病、脓毒症、休克、暴露于潜在的肾毒性药物和造影剂。临床终点包括AKI的发生率或分级、需要肾脏替代治疗和死亡率。根据国际GRADE系统将研究进行分级。

研究人员制定了12个推荐意见、13个建议和7个最佳实践声明。一些高水平证据的强烈建议大多是针对存在争议的干预(淀粉、低剂量多巴胺、心脏手术中的他汀类药物)。低水平证据的强烈建议包括采用晶体控制的液体复苏、避免液体超负荷、滴定去甲肾上腺素使MAP目标在65-70mmHg(除非慢性高血压)以及不使用利尿剂或左西孟旦进行单一肾脏保护。

由此可见,最近的随机对照试验的结果允许制定新的建议和/或增加以前的建议的强度。另一方面,在许多领域,现有可用的证据仍然不足,主要是由于质量受限的临床试验和报告的不良肾脏结局。

原始出处:

M. Joannidis, et al. Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017 : Expert opinion of the Working Group on Prevention, AKI section, European Society of Intensive Care Medicine.Intensive Care Medicine.2017. http://icmjournal.esicm.org/journals/abstract.html?v=0&j=134&i=0&a=4832_10.1007_s00134-017-4832-y&doi=

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1850612, encodeId=496c18506122a, content=<a href='/topic/show?id=46c682469e4' target=_blank style='color:#2F92EE;'>#肾功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82469, encryptionId=46c682469e4, topicName=肾功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Tue Oct 24 02:28:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038678, encodeId=f34a20386e88c, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Jul 31 12:28:00 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397211, encodeId=53ef139e2111e, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Tue Jun 06 10:28:00 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607615, encodeId=3da0160e615d6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jun 06 10:28:00 CST 2017, time=2017-06-06, status=1, ipAttribution=)]
    2017-10-24 yese
  2. [GetPortalCommentsPageByObjectIdResponse(id=1850612, encodeId=496c18506122a, content=<a href='/topic/show?id=46c682469e4' target=_blank style='color:#2F92EE;'>#肾功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82469, encryptionId=46c682469e4, topicName=肾功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Tue Oct 24 02:28:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038678, encodeId=f34a20386e88c, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Jul 31 12:28:00 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397211, encodeId=53ef139e2111e, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Tue Jun 06 10:28:00 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607615, encodeId=3da0160e615d6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jun 06 10:28:00 CST 2017, time=2017-06-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1850612, encodeId=496c18506122a, content=<a href='/topic/show?id=46c682469e4' target=_blank style='color:#2F92EE;'>#肾功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82469, encryptionId=46c682469e4, topicName=肾功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Tue Oct 24 02:28:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038678, encodeId=f34a20386e88c, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Jul 31 12:28:00 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397211, encodeId=53ef139e2111e, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Tue Jun 06 10:28:00 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607615, encodeId=3da0160e615d6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jun 06 10:28:00 CST 2017, time=2017-06-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1850612, encodeId=496c18506122a, content=<a href='/topic/show?id=46c682469e4' target=_blank style='color:#2F92EE;'>#肾功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82469, encryptionId=46c682469e4, topicName=肾功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Tue Oct 24 02:28:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038678, encodeId=f34a20386e88c, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Jul 31 12:28:00 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397211, encodeId=53ef139e2111e, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Tue Jun 06 10:28:00 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607615, encodeId=3da0160e615d6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jun 06 10:28:00 CST 2017, time=2017-06-06, status=1, ipAttribution=)]

相关资讯

Crit Care:危重患者心脏标志物与急性肾损伤的**分期相关!

由此可见,在非心脏原因入住ICU的危重病人中,入住ICU时的NT-proBNP水平与最高AKI分期和需要RRT之间具有最强的独立相关性。

KIDNEY INT:急性肾损伤与心肌梗死后微血管心肌损害有关!

因此,在血管再通的STEMI患者中,采用CMR评估的微血管损伤存在与AKI风险增加独立相关。这意味着心脏微血管病变与STEMI之后发生的肾损伤之间存在一个潜在的病理生理学联系。

Hypertension:非甾体激素受体拮抗剂finerenone防止急性肾损伤介导的慢性肾脏病

总之,该研究的数据表明,在大鼠中,finerenone能够预防由IR引起的急性肾损伤,以及肾脏结构和功能的长期和进展性恶化。

Chest:尿量的强化监测与增加急性肾损伤的检测和改善预后有关

在大型ICU人群中,强化UO监测与改善的AKI检测相关,并且可以降低发生AKI患者以及较少的液体超负荷的患者的30天死亡率。该研究结果应该有助于指导临床决策和ICU政策,关于监测UO频率,尤其是AKI和/或液体超负荷的高危患者。

Kidney Int:重组α-Klotho有望成为预防和治疗急性向慢性肾脏疾病发展及尿毒症性心肌病的新选择

α-Klotho高表达于肾脏,它的胞外区域可以被切断并释放到循环中。慢性肾脏疾病(CKD)的一个特征即为α-Klotho缺失,它对众多脏器表现出多重的负面系统效应,包括心血管系统。

KIDNEY INT:流行病学研究表明AKI的发病率并没有增加!

因此,尽管目前的文献表明AKI的流行,研究人员发现将年龄、性别进行调整后,在过去的十年间AKI的发病率在一般人群中保持相对稳定。

Baidu
map
Baidu
map
Baidu
map